具体来看，12月29日，北京瑞芬生物科技股份有限公司完成亿元级C轮融资，融资募集资金将主要用于 推动公司商业化开拓与全新产能建设落地，加速人类健康与动物健康双平台的研发创新、技术迭代与市 场拓展；上海心光生物医药有限责任公司(以下简称"心光生物")完成数千万元A1轮融资，资金将重点投 入再生型腹透产品即将开展的型检、临床和注册；博瑞策生物技术(上海)有限公司(以下简称"博瑞策生 物")宣布完成超1亿元A轮融资，用于加速GMP合规的生物安全检测平台建设与全球化布局。 稍早前，苏州血霁生物科技有限公司也宣布完成过亿元人民币B1轮股权融资并同步获得多家银行提供 的授信支持，资金将用于推进血小板体外再生这一核心技术方向，解决血源供应紧张等现实问题。 数据显示，2020年生物医药行业融资额高达2000亿元，然而到2024年，这一数字锐减至200亿元。在多 位业界人士看来，近期融资活跃度回升，意味着行业正在走出"资本寒冬"，进入了理性发展阶段。 临近年末，生物医药领域融资活动再度升温。12月29日，多家生物医药企业密集披露融资进展，释放出 行业投融资环境持续改善的信号。 南开大学金融学教授田利辉对《证券日报》记者表示，生 ...

Core Insights - Shanghai Xinguang Biomedical Co., Ltd. has completed a Pre-A++ financing round led by Xingfu Capital, marking its third financing in the past 12 months [1] - The funds will primarily be used to accelerate the mass production and registration of its portable dialysis machine [1] - The company aims to innovate in the dialysis field and establish a domestic technological barrier in China [2] Company Overview - Founded in 2018 at Fudan Science Park, the company focuses on making dialysis technology more accessible for over three million uremic patients globally [1] - The company emphasizes the need for disruptive innovation in the dialysis sector, particularly in the context of China's medical device industry [2] Industry Context - As of 2023, the total number of dialysis patients in China has exceeded 1.06 million, with an annual increase of 185,000 patients, reflecting a stable compound annual growth rate of 12% to 14% [1] - The dialysis industry faces challenges from centralized procurement policies that limit profit margins and the development of "Me too" products [2][3] - The company has achieved significant breakthroughs in large animal model experiments, gaining recognition from leading medical experts and investment institutions [3] Future Prospects - The company is working on a home dialysis solution that is cost-effective and improves dialysis adequacy through a dialysis fluid regeneration scheme [3] - Future plans include remote intelligent monitoring of the entire dialysis process and patient vital sign data monitoring, aiming to provide comprehensive treatment and follow-up management for end-stage renal disease patients [3]